Advertisement

Objective

Chapter
  • 297 Downloads
Part of the Springer Theses book series (Springer Theses)

Abstract

Structural information on the yCP alone and in complex with ligands strongly supported the development of the currently known potent CP inhibitors bortezomib and carfilzomib. Both compounds do not discriminate between the three mammalian CP types and, thereby, exert anti-cancer activity. However, recent studies demonstrate that iCP-specific inhibitors might qualify as therapeutics in autoimmune diseases. So far, only a few iCP-specific inhibitors were identified, mostly because structural data on the iCP were lacking.

Keywords

Amino Acid Substitution Adaptive Immune System Lead Structure Amino Acid Difference Medicinal Application 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Chair of BiochemistryTechnische Universität MünchenGarchingGermany

Personalised recommendations